
Pear Therapeutics has struck a deal to license voice biomarkers to try to improve treatment for patients with illnesses ranging from Alzheimer’s to insomnia and substance use disorder.
In a flurry of announcements Tuesday, the Boston-based company said it is licensing voice biomarker technology from Winterlight Labs Inc., a startup from Toronto that uses machine learning to pinpoint vocal changes associated with the onset of dementia and psychiatric diseases.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.